Outcomes with simultaneous administration of all-transretinoic acid (ATRA) plus chemotherapy-based regimens in children with newly diagnosed acute promyelocytic leukemia (APL).
| Cooperative Group, Reference . | Induction Regimen . | n . | Median Age (range) . | CR (%) . | 5-Year DFS % . | 5-Year CIR % . | 5-Year OS % . | Follow-up (months) . |
|---|---|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available | ||||||||
| German-Austrian-Swiss Mann et al (2001) | ATRA + Daunorubicin or Idarubicin | 22 | 9 (2–16) | 95 | NA | NA | 87 | 34 |
| European APL De Botton et al (2004) | ATRA + Daunorubicin + Cytarabine | 31 | 15 (1–17) | 97 | NA | 27 | 90 | 67 |
| GIMEMA Testi et al (2005) | ATRA + Idarubicin | 124 | 12 (2–17) | 96 | 78 | NA | 89 | 79 |
| PETHEMA Ortega et al (2005) | ATRA + Idarubicin | 66 | 12 (2–17) | 92 | 82 | 17 | 87 | 39 |
| Cooperative Group, Reference . | Induction Regimen . | n . | Median Age (range) . | CR (%) . | 5-Year DFS % . | 5-Year CIR % . | 5-Year OS % . | Follow-up (months) . |
|---|---|---|---|---|---|---|---|---|
| Abbreviations: CR, complete remission; DFS, disease-free survival; CIR, cumulative incidence of relapse; OS, overall survival; NA, not available | ||||||||
| German-Austrian-Swiss Mann et al (2001) | ATRA + Daunorubicin or Idarubicin | 22 | 9 (2–16) | 95 | NA | NA | 87 | 34 |
| European APL De Botton et al (2004) | ATRA + Daunorubicin + Cytarabine | 31 | 15 (1–17) | 97 | NA | 27 | 90 | 67 |
| GIMEMA Testi et al (2005) | ATRA + Idarubicin | 124 | 12 (2–17) | 96 | 78 | NA | 89 | 79 |
| PETHEMA Ortega et al (2005) | ATRA + Idarubicin | 66 | 12 (2–17) | 92 | 82 | 17 | 87 | 39 |